The effect of LHRH agonist therapy in the treatment of endometriosis (English experience).

article OA: closed CC0 ⤵ 9 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-07

Buserelin and danazol both reduced endometriosis lesion severity by modified AFS scores after seven months, with danazol causing more adverse effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The preliminary findings of a comparative study of buserelin and danazol in the treatment of endometriosis are presented. Eighty patients with laparoscopically proven symptomatic endometriosis have been allocated at random to open treatment with intra-nasal buserelin or oral danazol. Forty-five patients have been assessed after completion of seven months treatment. Changes in endometriotic lesions have been examined by second laparoscopy and scored according to a modification of the criteria of the American Fertility Society (AFS). Both treatments were associated with reductions in modified AFS scores reflecting partial resolution of the condition. Adverse effects were reported with the use of both drugs, but appeared to be more extensive during therapy with danazol. Further evaluation and post treatment follow up are required.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Danazol Endometriosis Pregnadienes Adolescent Adult Amenorrhea Amenorrhea Buserelin Buserelin Clinical Trials as Topic Danazol Danazol Endometriosis Endometriosis Female Humans Pregnadienes Prospective Studies Random Allocation

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (9)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:40.384591+00:00
License: CC0 · commercial use OK